



NDA 022090/S-019

SUPPLEMENT APPROVAL

Bayer Healthcare Pharmaceuticals Inc
Attention: Dolores Fliss
Director, Regulatory Affairs
100 Bayer Blvd.
P.O. Box 915
Whippany, NJ 07981-0915

Dear Ms. Fliss:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 26, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Eovist (gadoksetate disodium) injection.

This “Changes Being Effectuated” supplemental new drug application provides for provides for the addition of quantitative information of the drug product excipients in the labeling per the supplement request letter by the Agency dated February 25, 2021.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also, within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELS

We acknowledge your October 25, 2021, submission containing final printed carton and container labeling.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Lana Rossiter, Branch Chief, at (301) 796 – 6823 or Lana.Rossiter@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, PhD
Chief, Branch I
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling
Carton and Container Labeling



Ramesh
Raghavachari

Digitally signed by Ramesh Raghavachari
Date: 12/01/2021 08:59:20PM
GUID: 502d0913000029f375128b0de8c50020